Diagnostic Markers and Cytokine Profile in Rheumatoid Arthritis During Basic Therapy

Anvarxodjaeva Sh.G.; Eshmurzaeva A.A.

Authors

Anvarxodjaeva Sh.G. Tashkent State Medical University
Eshmurzaeva A.A. Tashkent State Medical University

Vol. 3 No. 8 (2025): International Journal of Integrative and Modern Medicine

Articles

August 5, 2025

Downloads

View Article

Abstract
How to Cite
Metrics
References

The aim of this study was to evaluate the diagnostic and prognostic significance of anti-mutated citrullinated vimentin (anti-MCV) antibodies, anti-keratin antibodies (AKA), and interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA) undergoing methotrexate-based therapy. A 12-month prospective observational study was conducted involving 76 patients with both early and established RA. A comprehensive assessment was performed, including clinical disease activity evaluation, serum levels of anti-MCV, AKA, rheumatoid factor (RF), and IL-6, as well as dynamic radiographic monitoring. Elevated levels of anti-MCV and IL-6 were found to be associated with high inflammatory activity and rapid progression of joint erosions. Notably, anti-MCV showed particular diagnostic value in patients with seronegative RA. A reduction in anti-MCV and IL-6 levels correlated with the achievement of clinical remission during therapy. The novelty of this study lies in demonstrating the prognostic value of anti-MCV and IL-6 as biomarkers for monitoring the long-term effectiveness of RA treatment.

Anvarxodjaeva Sh.G., & Eshmurzaeva A.A. (2025). Diagnostic Markers and Cytokine Profile in Rheumatoid Arthritis During Basic Therapy. International Journal of Integrative and Modern Medicine, 3(8), 20–28. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/2030

Download Citation

1. Ubshaeva YuB. Clinical features and management of rheumatoid arthritis with high levels of pro-inflammatory cytokines. Rheumatology Research. 2015.

2. Oransky SP, Eliseeva LN. Dynamics of serum cytokine and endothelial biomarkers in rheumatoid arthritis during course therapy. Fundamental Research. 2012;(12):112–6. Available from: https://s.fundamental-research.ru/pdf/2012/2012121.pdf#page=112

3. Avdeeva AS, Novikov AA, Ponomareva OV. Correlation between cytokine levels, disease activity, autoantibody levels, and destructive joint changes in early rheumatoid arthritis. Scientific and Practical Rheumatology. 2015;53(2):45–52. https://doi.org/10.14412/1995-4484-2015-488

4. Gavrilă BI, Ciofu C, Stoica V. Biomarkers in rheumatoid arthritis, what is new? J Med Life. 2016;9(2):144–8. Available from: https://pdfs.semanticscholar.org/2811/d69125f3cedf12b0180add0ab79f35f23bd4.pdf

5. López-Romero P, Martinez-Gamboa L, Bang H. Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with methotrexate. Arthritis Res Ther. 2020;22:284. https://doi.org/10.1186/s13075-020-02284-y

6. Ali DA, Al-Anee MM, Al-Anee NA. Assessment of the correlation between disease activity and serum biomarker Anti-MCV and IL6 in Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2024;66(1):41–8. Available from: https://www.iasj.net/iasj/download/5de6ef6e4bd9f7af

7. Zhu JN, Nie MJ, Li C, Deng YS, Zheng WX. Diagnostic value of anti-MCV antibodies in rheumatoid arthritis: A systematic review and meta-analysis. Clin Chem Lab Med. 2019;57(9):1289–98. https://doi.org/10.1515/cclm-2019-0167

8. Hassoon HJ, Abbas AAH, Jasim WE. Diagnostic value of anti-MCV antibodies in rheumatoid arthritis patients in Iraq. Iraqi J Sci. 2020;61(11):2850–7. Available from: https://www.iasj.net/iasj/download/8c6d28004a73a586

9. Ali OSM, Khalifa AIM, El-Shaer SSM. Study of the diagnostic value of anti-MCV and MMP3 biomarkers in serum and synovial fluid of rheumatoid arthritis patients. Int J Pharm Appl Sci. 2015;7(1):1–7. Available from: https://www.researchgate.net/publication/316066215

10. Reyes-Pérez IV, Sánchez-Hernández PE, Flores-Chávez A, et al. Serum cytokine profiles and their relationship with antibodies to citrullinated proteins in rheumatoid arthritis. Clin Rheumatol. 2019;38(12):3473–82. https://doi.org/10.1007/s10067-019-04681-4

11. Zahran WE, Mahmoud MI, Shalaby KA. Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: Diagnostic and prognostic significance. Egypt Rheumatol Rehabil. 2013;40(1):27–35. https://doi.org/10.4103/1110-161X.123796

12. Voronina MS, Vinogradov AA. Diagnostic markers and cytokine profile in rheumatoid arthritis against the background of basic therapy. Scientific and Practical Rheumatology. 2012;50(1):50–5. Available from: https://cyberleninka.ru/article/n/diagnosticheskie-markery-i-tsitokinovyy-profil-pri-revmatoidnom-artrite-na-fone-bazisnoy-terapii

13. López-Hoyos M, Calvo-Alén J. New autoantibodies in rheumatoid arthritis: Significance and clinical utility. Curr Opin Rheumatol. 2019;31(3):231–6. https://doi.org/10.1097/BOR.0000000000000583

14. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. https://doi.org/10.1016/S0140-6736(16)30173-8

International Journal of Integrative and Modern Medicine

Diagnostic Markers and Cytokine Profile in Rheumatoid Arthritis During Basic Therapy

Authors

Downloads

Similar Articles

submenu

counter